Nasdaq · CIK 0000744218
CLDX Celldex Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Jan 6, 2026. Close $29.89 on Oct 9, 2026, +32% from the 52-week low and -33% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
19
with a Form 4 at this company
Price and insider trades, last year
CLDXOct 9, 2026 · close 29.89
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Celldex Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Freddy A. Jimenez SVP & GENERAL COUNSEL sell | $121k 4,166 shares | -12% | +96% from low0% from high | |
| 38Weak | Richard M. Wright other sell | $1.2M 49,298 shares | -70% | +57% from low-16% from high | |
| 15Weak | Freddy A. Jimenez SVP & GENERAL COUNSEL sell | $19k 771 shares | -2% | +65% from low-43% from high | |
| 45Moderate | Anthony S Marucci PRESIDENT & CEO buy | $308k 11,500 shares | +40% | - |
Transactions
The last 36 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2026 | Samuel Bates Martin SVP AND CFO | MOption exercise Common Stock | +4,817 | $10.38 | $50k | 32,942 | Jan 6, 2026 |
| Jan 2, 2026 | Samuel Bates Martin SVP AND CFO | MOption exercise Incentive Stock Option (Right to Buy)derivative | -4,817 | $0.00 | $0 | 58,815 | Jan 6, 2026 |
| Dec 15, 2025 | Ronald Pepin SR. VP & CBO | MOption exercise Common Stock | +8,333 | $9.02 | $75k | 9,097 | Dec 17, 2025 |
| Dec 15, 2025 | Ronald Pepin SR. VP & CBO | MOption exercise Common Stock | +11,000 | $2.78 | $31k | 20,097 | Dec 17, 2025 |
| Dec 15, 2025 | Ronald Pepin SR. VP & CBO | MOption exercise Incentive Stock Option (right to buy)derivative | -8,333 | $0.00 | $0 | 5,000 | Dec 17, 2025 |
| Dec 15, 2025 | Ronald Pepin SR. VP & CBO | MOption exercise Incentive Stock Option (right to buy)derivative | -11,000 | $0.00 | $0 | 0 | Dec 17, 2025 |
| Dec 4, 2025 | Freddy A. Jimenez SVP & GENERAL COUNSEL | SOpen-market sale Common Stock | -4,166 | $29.10 | $121k | 30,796 | Dec 8, 2025 |
| Nov 13, 2025 | Richard M. Wright other | MOption exercise Common Stock | +6,876 | $9.02 | $62k | 27,709 | Nov 17, 2025 |
| Nov 13, 2025 | Richard M. Wright other | MOption exercise Common Stock | +26,672 | $10.38 | $277k | 54,381 | Nov 17, 2025 |
| Nov 13, 2025 | Richard M. Wright other | MOption exercise Common Stock | +15,750 | $22.48 | $354k | 70,131 | Nov 17, 2025 |
| Nov 13, 2025 | Richard M. Wright other | SOpen-market sale Common Stock | -49,298 | $24.00 | $1.2M | 20,833 | Nov 17, 2025 |
| Nov 13, 2025 | Richard M. Wright other | MOption exercise Incentive Stock Optionderivative | -6,876 | $0.00 | $0 | 0 | Nov 17, 2025 |
| Nov 13, 2025 | Richard M. Wright other | MOption exercise Incentive Stock Optionderivative | -26,672 | $0.00 | $0 | 0 | Nov 17, 2025 |
| Nov 13, 2025 | Richard M. Wright other | MOption exercise Incentive Stock Optionderivative | -15,750 | $0.00 | $0 | 7,875 | Nov 17, 2025 |
| Nov 10, 2025 | Teri L Lawver SVP & Chief Commercial Officer | AGrant or award ISO (right to buy)derivative | +100,000 | $0.00 | $0 | 100,000 | Nov 12, 2025 |
| Aug 13, 2025 | Freddy A. Jimenez SVP & GENERAL COUNSEL | SOpen-market sale Common Stock | -341 | $23.95 | $8,167 | 35,392 | Aug 15, 2025 |
| Aug 13, 2025 | Freddy A. Jimenez SVP & GENERAL COUNSEL | SOpen-market sale Common Stock | -430 | $25.42 | $11k | 34,962 | Aug 15, 2025 |
| Jun 5, 2025 | Elizabeth Crowley SR. VP & CPDO | AGrant or award Incentive Stock Option (right to buy)derivative | +85,000 | $0.00 | $0 | 85,000 | Jun 9, 2025 |
| Jun 5, 2025 | Herbert J Conrad director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Jun 5, 2025 | Margo Heath-Chiozzi SVP OF REGULATORY AFFAIRS | AGrant or award Incentive Stock Option (right to buy)derivative | +82,000 | $0.00 | $0 | 82,000 | Jun 9, 2025 |
| Jun 5, 2025 | Freddy A. Jimenez SVP & GENERAL COUNSEL | AGrant or award Incentive Stock Option (right to buy)derivative | +75,000 | $0.00 | $0 | 75,000 | Jun 9, 2025 |
| Jun 5, 2025 | Samuel Bates Martin SVP AND CFO | AGrant or award Incentive Stock Option (right to buy)derivative | +81,000 | $0.00 | $0 | 81,000 | Jun 9, 2025 |
| Jun 5, 2025 | Ronald Pepin SR. VP & CBO | AGrant or award Incentive Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Jun 9, 2025 |
| Jun 5, 2025 | Diane C. Young SVP, CHIEF MEDICAL OFFICER | AGrant or award Incentive Stock Option (right to buy)derivative | +72,000 | $0.00 | $0 | 72,000 | Jun 9, 2025 |
| Jun 5, 2025 | Tibor Keler EXECUTIVE VP & CSO | AGrant or award Incentive Stock Option (right to buy)derivative | +93,000 | $0.00 | $0 | 93,000 | Jun 9, 2025 |
| Jun 5, 2025 | Anthony S Marucci PRESIDENT & CEO | AGrant or award Incentive Stock Option (right to buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Jun 9, 2025 |
| Jun 5, 2025 | Denice Torres director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +33,000 | $0.00 | $0 | 33,000 | Jun 9, 2025 |
| Jun 5, 2025 | Rita Jain director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Jun 5, 2025 | Garry Arthur Neil director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Jun 5, 2025 | Harry Penner Jr director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Jun 5, 2025 | James J Marino director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Jun 5, 2025 | Cheryl Cohen director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Jun 5, 2025 | Sarah Cavanaugh SVP OF CORP AFFAIRS & ADMIN. | AGrant or award Incentive Stock Option (right to buy)derivative | +78,000 | $0.00 | $0 | 78,000 | Jun 9, 2025 |
| Jun 5, 2025 | Keith L Brownlie director | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +16,500 | $0.00 | $0 | 16,500 | Jun 9, 2025 |
| Nov 18, 2024 | James J Marino director | GGift Common Stock | -10,500 | $0.00 | $0 | 2,204 | Nov 20, 2024 |
| Nov 11, 2024 | Anthony S Marucci PRESIDENT & CEO | POpen-market purchase Common Stock | +11,500 | $26.82 | $308k | 40,284 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Keith L Brownliedirector
- Herbert J Conraddirector
- Sarah CavanaughSVP OF CORP AFFAIRS & ADMIN.
- Cheryl Cohendirector
- Elizabeth CrowleySR. VP & CPDO
- Margo Heath-ChiozziSVP OF REGULATORY AFFAIRS
- Rita Jaindirector
- Freddy A. JimenezSVP & GENERAL COUNSEL
- Tibor KelerEXECUTIVE VP & CSO
- Teri L LawverSVP & Chief Commercial Officer
- James J Marinodirector
- Samuel Bates MartinSVP AND CFO
- Anthony S MarucciPRESIDENT & CEO
- Garry Arthur Neilceo, chair, officer, director
- Harry Penner Jrdirector
- Ronald PepinSR. VP & CBO
- Denice Torresdirector
- Richard M. Wrightother
- Diane C. YoungSVP, CHIEF MEDICAL OFFICER
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.